Lorenzo-Vizcaya, A;
Fasano, S;
Isenberg, DA;
(2020)
Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
ImmunoTargets and Therapy
, 9
pp. 105-110.
10.2147/ITT.S240874.
Preview |
Text
itt-240874-bruton-rsquo-s-tyrosine-kinase-inhibitors-xfeff-a-new-the.pdf - Published Version Download (248kB) | Preview |
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease with a complex pathogenesis, which presents a great variability in its presentation and can affect almost all organs and systems. Multiple therapeutic targets have been discovered recently, but there also have been failed attempts to treat SLE using biologic agents. Bruton’s tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase expressed in several types of cells of hematopoietic origin which participate in both innate and adaptive immunity. Ibrutinib, a BTK inhibitor, is approved for the treatment of several B cell malignancies, including some types of lymphoma and leukemia. As BTK is expressed on several immune cell types, the mechanism of action of BTK also suggests the use of BTK inhibitors in the treatment of autoimmune diseases. In this review, we will summarize what is known and what has been published so far about the treatment of mouse models of SLE and the human disease, using BTK inhibitors.
| Type: | Article |
|---|---|
| Title: | Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE? |
| Location: | New Zealand |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.2147/ITT.S240874 |
| Publisher version: | https://doi.org/10.2147/ITT.S240874 |
| Language: | English |
| Additional information: | This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. https://creativecommons.org/licenses/by-nc/3.0/ |
| Keywords: | lupus, Bruton, tyrosine kinase, therapeutic targeting, ibrutinib, fenebrutinib |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10110500 |
Archive Staff Only
 |
View Item |
